This section highlights FDA-related milestones and regulatory updates for drugs developed by Phathom Pharmaceuticals (PHAT).
Over the past two years, Phathom Pharmaceuticals has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
VOQUEZNA and vonoprazan. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
VOQUEZNA FDA Regulatory Events
VOQUEZNA is a drug developed by Phathom Pharmaceuticals for the following indication: or the relief of heartburn associated with Non-Erosive GERD in adults.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- VOQUEZNA
- Announced Date:
- October 23, 2026
- Indication:
- or the relief of heartburn associated with Non-Erosive GERD in adults
Announcement
Phathom Pharmaceuticals, Inc announced today that BDR Pharmaceuticals International Pvt. Ltd. (BDR) has filed suit against the U.S. Food and Drug Administration (FDA) and related Federal Defendants in the United States District Court for the District of Columbia, principally challenging FDA’s alleged refusal to receive an abbreviated new drug application (ANDA) referencing Phathom’s new drug application (NDA) for VOQUEZNA®.
Read Announcement
Vonoprazan FDA Regulatory Timeline and Events
Vonoprazan is a drug developed by Phathom Pharmaceuticals for the following indication: For the Treatment of Heartburn Associated with Non-Erosive GERD.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- vonoprazan
- Announced Date:
- October 12, 2026
- Indication:
- For the Treatment of Heartburn Associated with Non-Erosive GERD
Announcement
Phathom Pharmaceuticals, Inc. announced new cost-effectiveness data for VOQUEZNA® (vonoprazan), alongside additional clinical and real-world data, presented at the American College of Gastroenterology’s (ACG) 2026 Annual Scientific Meeting, being held October 9-14 in Nashville, Tennessee.
AI Summary
Phathom Pharmaceuticals presented new VOQUEZNA (vonoprazan) findings at the American College of Gastroenterology’s 2026 meeting. A model projecting lifetime outcomes for adults with erosive GERD found that VOQUEZNA could lead to fewer serious complications than proton pump inhibitors (PPIs). At estimated net prices, it was projected to save healthcare costs; at list price, it was projected to be cost-effective, with estimated costs of $28,402 per added quality-adjusted life-year for the overall group and $18,878 for severe cases. These are model-based projections, not confirmed real-world savings.
Other Phathom-sponsored research found VOQUEZNA improved heartburn across BMI groups in non-erosive GERD, with BMI not changing the treatment effect. A U.S. records study found people starting VOQUEZNA generally had more severe GERD than those starting prescription PPIs, including more erosive disease and prior PPI treatment. Researchers also presented 38 independent abstracts on vonoprazan across reflux, H. pylori treatment, ulcers, and other digestive conditions.
Read Announcement- Drug:
- vonoprazan
- Announced Date:
- October 8, 2026
- Indication:
- For the Treatment of Heartburn Associated with Non-Erosive GERD
Announcement
Phathom Pharmaceuticals, Inc announced its participation in the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, being held October 9-14 in Nashville, Tennessee.
AI Summary
Phathom Pharmaceuticals, Inc. will take part in the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, October 9–14 in Nashville, Tennessee. The company plans to share three new analyses of VOQUEZNA (vonoprazan), its treatment for gastroesophageal reflux disease (GERD).
The presentations will examine how VOQUEZNA works across body mass index groups in people with non-erosive GERD, describe real-world characteristics of U.S. patients taking vonoprazan or prescription proton pump inhibitors, and compare the medicines’ cost-effectiveness for adults with erosive esophagitis. The posters are scheduled for October 11, 12, and 13.
Phathom will also host a product theater on October 12, featuring discussion of VOQUEZNA’s clinical results, safety, patient cases, and patient perspectives. Company representatives will be available at Booth 323. CEO Steve Basta said the meeting offers a chance to share new findings and hear from clinicians and patients. The analyses are intended to add to the evidence about VOQUEZNA’s use in GERD.
Read Announcement- Drug:
- vonoprazan
- Announced Date:
- September 29, 2026
- Indication:
- For the Treatment of Heartburn Associated with Non-Erosive GERD
Announcement
Phathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of VOQUEZNA® (vonoprazan) tablets in adults with Non-Erosive Gastroesophageal Reflux Disease, or Non-Erosive GERD (NERD).
AI Summary
Phathom Pharmaceuticals has begun screening patients for pHalcon-NERD-302, a registrational Phase 3 trial of VOQUEZNA (vonoprazan) taken as needed by adults with non-erosive gastroesophageal reflux disease (NERD). The study builds on positive Phase 2 results and will test whether the medicine can provide quick heartburn relief that lasts for 24 hours. The company expects to enroll about 500 adults at roughly 80 U.S. sites.
After a four-week period taking VOQUEZNA daily, eligible participants will be assigned to take 10 mg of VOQUEZNA or a placebo as needed for 24 weeks. The main measure is the share of heartburn episodes with complete relief within two hours and continued relief for 24 hours. Topline results are expected in the first quarter of 2028. If successful, the trial could support a request to expand VOQUEZNA’s label to include as-needed treatment for heartburn in adults with NERD, offering an alternative to continuous daily therapy.
Read Announcement- Drug:
- vonoprazan
- Announced Date:
- June 23, 2026
- Indication:
- For the Treatment of Heartburn Associated with Non-Erosive GERD
Announcement
Phathom Pharmaceuticals, Inc. announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults.
AI Summary
Phathom Pharmaceuticals said it has finished enrolling patients in its Phase 2 pHalcon-EoE-201 clinical trial of VOQUEZNA (vonoprazan) tablets for adults with eosinophilic esophagitis, or EoE. The company says this is the first large, placebo-controlled study of an acid-suppressing treatment in EoE, a long-term condition that can make swallowing difficult and cause inflammation in the esophagus. The trial uses a double-blind design and will test whether VOQUEZNA may help treat the disease. Topline results from the 12-week treatment period are expected in the fourth quarter of 2026. Phathom also said more details about the study are available on ClinicalTrials.gov under NCT06851559. The announcement adds to ongoing research into whether acid suppression can play a useful role in treating EoE in adults.
Read Announcement- Drug:
- vonoprazan
- Announced Date:
- May 20, 2026
- Indication:
- For the Treatment of Heartburn Associated with Non-Erosive GERD
Announcement
Phathom Pharmaceuticals, Inc today highlighted the growing body of clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA® (vonoprazan), at Digestive Disease Week (DDW) 2026, held May 2–5, 2026 in Chicago, Illinois.
AI Summary
Phathom Pharmaceuticals highlighted new clinical and scientific research on vonoprazan, the key ingredient in VOQUEZNA, at Digestive Disease Week 2026 in Chicago from May 2–5. The company said the drug’s use continues to grow, with more than one million prescriptions filled in the U.S. since launch. VOQUEZNA is approved for adults with erosive esophagitis, heartburn linked to GERD, and H. pylori infection when used with antibiotics.
Phathom also pointed to progress in its development pipeline, including a Phase 2 study of vonoprazan for eosinophilic esophagitis, which began in November 2025. Early results from that trial are expected in 2027. The company said it expects to reach operating profitability in the second half of 2026 and is raising funds to support commercialization, research, and general operations.
Read Announcement- Drug:
- vonoprazan
- Announced Date:
- October 25, 2025
- Indication:
- For the Treatment of Heartburn Associated with Non-Erosive GERD
Announcement
Phathom Pharmaceuticals, Inc. announced that results of additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA® (vonoprazan) tablets in patients with Non-Erosive Reflux Disease (NERD) have been published in the American Journal of Gastroenterology.
AI Summary
Phathom Pharmaceuticals announced new results from its Phase 3 pHalcon-NERD-301 trial in the American Journal of Gastroenterology. The study focused on VOQUEZNA® (vonoprazan) tablets for patients with Non-Erosive Reflux Disease (NERD).
In the trial, 772 patients were randomly assigned to VOQUEZNA 10 mg, 20 mg, or placebo for four weeks. After that, VOQUEZNA groups continued treatment for 20 weeks, and placebo patients switched to VOQUEZNA.
Results showed rapid relief of nighttime GERD symptoms. Over 50% of VOQUEZNA patients had heartburn-free nights after the first dose, compared to 32% on placebo. These gains held through 24 weeks, with median heartburn-free nights above 70%.
Exploratory measures also improved. Patients reported lower nighttime symptom severity and fewer sleep disturbances throughout treatment.
VOQUEZNA was generally well tolerated, with low rates of mild side effects such as nausea and abdominal pain.
Read Announcement- Drug:
- vonoprazan
- Announced Date:
- October 23, 2025
- Indication:
- For the Treatment of Heartburn Associated with Non-Erosive GERD
Announcement
Phathom Pharmaceuticals, Inc. announced its participation in the American College of Gastroenterology's (ACG) 2025 Annual Scientific Meeting, being held October 24-29 in Phoenix, Arizona.
AI Summary
Phathom Pharmaceuticals, Inc. will participate in the American College of Gastroenterology’s 2025 Annual Scientific Meeting, October 24–29 in Phoenix, Arizona. The company plans to highlight its growing leadership in gastrointestinal disease treatments.
Phathom’s Medical Affairs and Commercial teams will staff Exhibit Booth #214 from October 26–29, giving attendees a chance to learn about VOQUEZNA® (vonoprazan) tablets. On Monday, October 27 (3:45–4:30 pm MST), Dr. John Erik Pandolfino will lead a VOQUEZNA® product theater titled “Expert Insights on GERD Therapy: A Case-Based Approach with a First-in-Class Acid Suppressant.”
Phathom also provided an independent medical education grant for a hybrid Medscape program, “Decision Points in the Management of GERD,” held Saturday, October 25, featuring faculty Charles P. Vega, MD; Rena Yadlapati, MD; and Prakash Gyawali, MD.
Steve Basta, Phathom’s President and CEO, said ACG offers a valuable forum to share clinical insights, engage experts, and reinforce the company’s commitment to improving patient outcomes in GI disorders.
Read Announcement- Drug:
- vonoprazan
- Announced Date:
- June 16, 2025
- Indication:
- For the Treatment of Heartburn Associated with Non-Erosive GERD
Announcement
Phathom Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has updated the Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") to accurately reflect the full 10-year period of non-patent New Chemical Entity (NCE) exclusivity for VOQUEZNA® (vonoprazan) 10 mg and 20 mg tablets.
AI Summary
Phathom Pharmaceuticals announced that the FDA has updated the Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”) to correctly show the full 10-year period of non-patent New Chemical Entity (NCE) exclusivity for VOQUEZNA® (vonoprazan) 10 mg and 20 mg tablets. This update confirms that VOQUEZNA is entitled to NCE regulatory exclusivity until May 3, 2032.
This correction aligns the Orange Book listing with statutory requirements and reinforces the long-term commercial prospects for the first-in-class treatment. The clarification provides a stable regulatory framework for VOQUEZNA, ensuring that its exclusive market status in treating gastrointestinal conditions is maintained over its full period of protection.
Read Announcement- Drug:
- vonoprazan
- Announced Date:
- June 6, 2025
- Indication:
- For the Treatment of Heartburn Associated with Non-Erosive GERD
Announcement
Phathom Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition filed on December 11, 2024 and communicated the Agency's intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032.
AI Summary
Phathom Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved its Citizen Petition filed on December 11, 2024. The FDA stated its plans to update the Orange Book to correctly reflect a full 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets. This exclusivity period will now extend through May 3, 2032, ensuring that the drug receives proper recognition and protection as a first-in-class treatment. With this update, Phathom confirms that VOQUEZNA® will maintain its market exclusivity during this period, solidifying its competitive advantage in treating conditions such as heartburn and gastroesophageal reflux disease. This decision from the FDA supports the company’s ongoing efforts to secure market rights and highlights the value of VOQUEZNA® in the treatment of gastrointestinal diseases.
Read Announcement- Drug:
- vonoprazan
- Announced Date:
- April 28, 2025
- Indication:
- For the Treatment of Heartburn Associated with Non-Erosive GERD
Announcement
Phathom Pharmaceuticals, Inc announced that the company will present real-world data for its first-in-class treatment VOQUEZNA® (vonoprazan) at Digestive Disease Week® (DDW) being held May 3–6, 2025, in San Diego, CA.
AI Summary
Phathom Pharmaceuticals, Inc. will present new real-world data on its first-in-class treatment, VOQUEZNA® (vonoprazan), at Digestive Disease Week® (DDW) in San Diego, CA from May 3–6, 2025. The data focuses on how VOQUEZNA is being used in everyday clinical practice by U.S. patients diagnosed with gastroesophageal reflux disease (GERD), including both Non-Erosive and Erosive forms. Highlighting the treatment's unique benefits, the presentation aims to provide insights into patient characteristics and treatment patterns that differentiate VOQUEZNA from traditional proton pump inhibitors. Additionally, Phathom will showcase two sponsored posters on May 5, and host a Product Theater session, offering healthcare professionals a closer look at the real-world efficacy and potential role of VOQUEZNA in improving symptom control for GERD patients.
Read Announcement- Drug:
- vonoprazan
- Announced Date:
- December 11, 2024
- Indication:
- For the Treatment of Heartburn Associated with Non-Erosive GERD
Announcement
Phathom Pharmaceuticals, Inc announced today it has submitted a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA).
AI Summary
Phathom Pharmaceuticals announced today that it has submitted a Citizen Petition to the U.S. Food and Drug Administration (FDA). The petition requests that the FDA correct the Orange Book listings for VOQUEZNA (vonoprazan) tablets to reflect the full 10‐year New Chemical Entity (NCE) exclusivity period, which ends on May 3, 2032. Phathom argues that since VOQUEZNA tablets contain the same active ingredient as the VOQUEZNA TRIPLE PAK and DUAL PAK products—which were granted a 10-year exclusivity period under the GAIN Act—all vonoprazan-based products should benefit equally. The company believes that the current listings do not accurately show the full period of exclusivity as mandated by law. The FDA is expected to review the petition and respond within 180 days from submission.
Read Announcement